The past decade saw a plethora of studies highlighting the dysregulation of MNX1 in various cancers, including leukaemia [9], lymphoma [10], cancers of the breast [11,12], prostate [13], bladder [14], colorectal [15], brain [16,17], hepatocellular carcinomas [18], and pancreatic tumours [19]. Here, MNX1 is linked to hepatocellular carcinoma.